ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2588

Myositis-specific and -associated Antibodies in Systemic Sclerosis: Prevalence and Clinical Associations

Amélie Leurs 1, Sylvain Dubucquoi 1, François Machuron 1, Maité Balden 1, Florence Renaud 1, Stéphanie Rogeau 1, Benjamin Lopez 2, Marc LAMBERT 3, Sandrine Morell-Dubois 4, Hélène Maillard 4, Hélène Behal 1, Eric Hachulla 5, David Launay 1 and Vincent Sobanski1, 1CHU Lille, Lille, France, 2Institute of Immunology, CHU Lille, University of Lille, Lille, France, 3Lille University Hospital, Lille, France, 4Department of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, Lille, France, 5Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: ,

Session Information

Date: Tuesday, November 12, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM), auto-antibodies are used in daily practice as potent biomarkers of clinical phenotypes. This study aimed at estimating the prevalence of myositis-specific (MSA) and myositis-associated (MAA) autoantibodies in SSc, and studying their clinical associations.

Methods: We realized a cross-sectional, observational, single-center study. The sera of 300 consecutive patients were tested with myositis antibodies Euroimmun® and D-tek® immunoblot assays to estimate prevalence of MSA and MAA and study their clinical associations.

Results: Prevalence of MSA/MAA, MSA and MAA were 17%, 8.0% and 9.7%, respectively. Anti-PM/Scl 100 were found in 5.0% (95% confidence interval 2.8; 8.1); anti-PM/Scl 75 and anti-TIF1γ in 3.7% (1.8; 6.5); anti-Ku 3.0% (1.4; 5.6); anti-MDA5 in 1.3% (0.4; 3.4); anti-Mi-2β, anti-NXP2, anti-PL7 and anti-SRP in 0.7% (0.08; 2.4); anti-EJ and anti-PL-12 in 0.3% (0.01; 1.8) of patients. No reactivity against SAE1, Jo-1 or OJ was observed (Figure 1). Anti-PM/Scl 75 antibodies were associated with interstitial lung disease (80% vs 42%, p = 0.022) and myositis (27% vs 3%, p = 0.005); anti-PM/SCL 100 antibodies were associated with abdominal discomfort (38% vs 8%, p = 0.029); anti-Ku antibodies were associated with myositis (33% vs 3%, p = 0.003). There was a trend towards an association between anti-TIF1γ and cancer (27% vs 8%, p = 0.060) (Figure 2).

Conclusion: In this cross-sectional study of 300 SSc patients, the prevalence of MSA/MAA, MSA and MAA were 17%, 8.0% and 9.7%, respectively. MAA positivity was associated with ILD and myositis, but this study did not highlight any clinical associations with MSA positivity.

Figure 1. Distribution of patients with positive MSA and MAA in this cross-sectional study of 300 SSc patients. -A- Prevalence of MSA and MAA with EUROLINE, D-TEK immunoblot assays and after agreement. -B- Heatmap of the MSA and MAA immunoblot assay reactivities among patients.
EJ: anti-glycyltRNA synthetase; Jo-1: anti-histidyl-tRNA synthetase; Ku: anti-DNA-dependent protein kinase; MAA, myositis associated antibodies; MDA5: anti-melanoma differentiation-associated gene 5; Mi-2: Anti-nuclear helicase/ATPase; MSA, myositis specific antibodies; OJ: anti-isoleucyl-tRNA synthetase; PM/Scl: anti-polymyositis scleroderma antigen; NXP2: anti-nuclear matrix protein 2; PL-7: anti-threonyl-tRNA synthetase; PL-12: anti-alanyl-tRNA synthetase; SRP: anti-signal recognition particle; TIF1γ: anti-transcriptional intermediary factor 1 gamma

Figure 2: Main characteristics of MSA and MAA positive patients in in this cross-sectional study of 300 SSc patients.
EJ: anti-glycyltRNA synthetase; ILD, interstitial lung disease; Jo-1: anti-histidyl-tRNA synthetase; Ku: anti-DNA-dependent protein kinase; MAA, myositis associated antibodies; MDA5: anti-melanoma differentiation-associated gene 5; Mi-2 β: Anti-nuclear helicase/ATPase Béta; MSA, myositis specific antibodies; OJ: anti-isoleucyl-tRNA synthetase; PH, pulmonary hypertension; PM/Scl: anti-polymyositis scleroderma antigen; NXP2: anti-nuclear matrix protein 2; PL-7: anti-threonyl-tRNA synthetase; PL-12: anti-alanyl-tRNA synthetase; SRP: anti-signal recognition particle; TIF1γ: anti-transcriptional intermediary factor 1 gamma.

Disclosure: A. Leurs, None; S. Dubucquoi, None; F. Machuron, None; M. Balden, None; F. Renaud, None; S. Rogeau, None; B. Lopez, None; M. LAMBERT, None; S. Morell-Dubois, None; H. Maillard, None; H. Behal, None; E. Hachulla, Actelion, 2, 5, Bayer, 2, 5, Chugai Pharma France, 8, GSK, 2, 5, Pfizer, 2, 5, Roche SAS, 5; D. Launay, Actelion, 8, GSK, 8, Octapharma, 8, Pfizer, 8, Shire, 8; V. Sobanski, Actelion, 8, Grifols, 8, GSK, 8, octapharma, 8, Pfizer, 8, shire, 8.

To cite this abstract in AMA style:

Leurs A, Dubucquoi S, Machuron F, Balden M, Renaud F, Rogeau S, Lopez B, LAMBERT M, Morell-Dubois S, Maillard H, Behal H, Hachulla E, Launay D, Sobanski V. Myositis-specific and -associated Antibodies in Systemic Sclerosis: Prevalence and Clinical Associations [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/myositis-specific-and-associated-antibodies-in-systemic-sclerosis-prevalence-and-clinical-associations/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/myositis-specific-and-associated-antibodies-in-systemic-sclerosis-prevalence-and-clinical-associations/